|
Market Closed -
Nasdaq
00:00:00 31/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 4.110 USD | -2.84% |
|
-0.48% | +44.21% |
| 09-21 | Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to S&P Global BMI Index | CI |
| 09-01 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
Company Valuation: Oramed Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 543.9 | 470.6 | 93.18 | 97.56 | 113.4 | 171 |
| Change | - | -13.48% | -80.2% | 4.69% | 16.28% | 50.71% |
| Enterprise Value (EV) | 543.9 | 470.6 | 93.18 | 97.56 | 113.4 | 171 |
| Change | - | -13.48% | -80.2% | 4.69% | 16.28% | 50.71% |
| P/E | -46.1x | -12.8x | 16.5x | -5.04x | 1.9x | 0.92x |
| PBR | - | - | - | - | - | - |
| PEG | - | -0x | -0x | 0x | -0x | 0x |
| Capitalization / Revenue | 602x | 174x | 69.5x | - | 56.7x | - |
| EV / Revenue | 0x | 0x | 0x | - | 0x | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | -0x | -0x | -0x | -0x | -7.4x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.31 | -0.94 | 0.14 | -0.48 | 1.5 | 4.47 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.904 | 2.703 | 1.34 | - | 2 | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -40.6 | -15.77 | -12.78 | -15.09 | -23.1 |
| Net income 1 | - | -36.56 | 5.525 | -19.06 | 64.05 | 188.6 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 14.280 | 12.030 | 2.310 | 2.420 | 2.850 | 4.110 |
| Nbr of stocks (in thousands) | 38,086 | 39,115 | 40,339 | 40,312 | 39,802 | 41,597 |
| Announcement Date | 30/03/22 | 06/03/23 | 06/03/24 | 27/03/25 | 26/03/26 | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.92x | - | - | - | 171M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.86x | 0.86% | 54.62B | |
| 34.85x | 3.31x | 14.29x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -71.62x | 13.03x | -68.47x | -.--% | 24.7B | |
| Average | 15.70x | 28.01x | 7.09x | 0.34% | 39.45B | |
| Weighted average by Cap. | 21.63x | 26.34x | 11.23x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ORMP Stock
- Valuation Oramed Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
